A new Treatment with T cells of the CMA receptor (CAR) called AIC100, which aims at ICAM-1 protein, has shown encouraging reactions and accepted safety profiles in patients with two types of advanced thyroid cancer, according to Centor Center Center.
The results from the Human Phase I test were presented today at the American Union Annual Meeting on Cancer Research (AACR) by the main researcher Samer Srour, MB CHB, Associate Professor of Stem Cell Transplantation and Cellular Therapy.
Possible promising early results in thyroid cancer (ATC) and recurrent/resistant poorly differentiated thyroid cancers (PTDC) – which have limited treatment options and poor forecasts – show progress in the progress of the benefits of the treatments. For nine patients receiving a 2 or 3 dose level, 22% were observed to have a significant tumor shrinkage and 56% had control of their disease.
The observed responses to the two dose groups were encouraging and provide a proof of the concept of the AIC100 potential in dealing with these very aggressive thyroid cancers. This type of cancer is one of the most deadly and most aggressive cancers and, with current limited treatment options, most patients have a sad prognosis of six months or less. ”
SAMER SROUR, MB CHB, Associate Professor of Stem Cell Transplantation & Cell Therapy
The AIC100 is a third-generation T cell treatment that operates on ICAM-1 in volume cells to eliminate them. The car-produced car produces a protein, called the Somatostatin 2 receptor, which allows clinicians to monitor the efficacy of treatment with specialized positron emission tomography (RET).
The multicenter test was involved in 24 adult patients with newly diagnosed or recurrent/durable ATC and recurrent/resistant PTDC with measurable disease. Fifteen patients received AIC100 from cutting data on December 12, 2024. Patients had averaged two previous systematic treatment lines. Researchers began evaluating three AIC100 dose levels. Patients received intravenous treatment at least 48 hours after three days of typical lympholepe.
There were no responses after treatment with dose level 1. Among the four patients with ATC at 2 and 3 dose levels, the total objective response rate was 50%. There was a patient in the level 2 of the dose 2 with a partial response and a patient in the dose group with complete response. Both remained without evidence of up to five and seven months from treatment, respectively. Between five patients with PDTC receiving 2 and 3 dose levels, the rate of disease control was 60%.
No dose restriction toxicities were observed in initially scheduled three dose levels. Ten patients developed 1/2 (CRS) release syndrome. There were no severe adverse events at dose levels 1-3 and no patient developed icans, a neuropsychiatric condition that may be a side effect of Cell T-cell treatment. Based on the effects of efficacy and safety, the researchers investigated a fourth level of dose, in which two patients developed grade 3 pulmonitis.
Based on the safety and efficiency observed, the dose level was chosen as the recommended dose for a future phase II test.
“These results really bring hope that we may work to bring a potentially effective new treatment option for patients with thyroid cancer,” Srour said. “While it is still early, having a complete recession and a partial answer provides a strong basis to use, for us and other researchers, to improve the results and possibly cause resistant violations for this very aggressive disease.”
The test was supported by Affyimmune Therapeutics.
